Advertisement
Product › Details
Avelox®
Next higher product group | moxifloxacin (INN) | |
Status | 1999-01-01 sales planned | |
Organisation | Bayer (Group) | |
Organisation 2 | Bayer AG | |
Group | Bayer (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for anti-infective drug
- [1] Basilea Pharmaceutica Ltd.. (4/4/24). "Press Release: Basilea Announces US FDA Approval of Antibiotic Zevtara (ceftobiprole medocaril) for Three Indications". Allschwil....
- [2] ProBioGen AG. (3/13/24). "Press Release: ProBioGen Partners with Mapp Biopharmaceutical, Inc. for Groundbreaking Development of Afucosylated Antibody against Marburg Virus Disease Using GlymaxX Technology". Berlin....
- [3] Omnix Medical Ltd.. (2/20/24). "Press Release: Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6". Jerusalem....
- [4] Memo Therapeutics AG. (11/16/23). "Press Release: Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer". Schlieren....
- [5] Glox Therapeutics Ltd.. (11/14/23). "Press Release: Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria". Glasgow....
- [6] Memo Therapeutics AG. (11/02/23). "Press Release: Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients". Schlieren....
- [7] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
- [8] Abivax S.A.. (8/23/23). "Press Release: Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations". Paris....
- [9] AiCuris Anti-infective Cures AG. (8/23/23). "Press Release: AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of Prevymis (letermovir) in Second Indication". Wuppertal....
- [10] AiCuris Anti-infective Cures AG. (7/6/23). "Press Release: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients". Wuppertal....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top